Sarepta Therapeutics Inc. (Nasdaq: SRPT) will submit a New Drug Application for its Duchenne Muscular Dystrophy treatment eteplirsen by the end of 2014. Shares of the biopharmaceutical leaped $10.85 to $35.25.
Sarepta To Submit NDA
April 21, 2014 at 14:08 PM EDT
